Compare Incyte Corporation (INCY) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Toronto-Dominion Bank — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Toronto-Dominion Bank trades at $120.5 (market cap $197.03B). The key difference: Toronto-Dominion Bank is far larger — about 8.5× Incyte Corporation's market cap, and Toronto-Dominion Bank pays a 2.62% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TD | |
|---|---|---|
Market Cap | $23.11B | $197.03B |
Sector | Health | Financials |
52-Week High | $118.52 | $124.80 |
52-Week Low | $67.38 | $72.55 |
Enterprise Value | $19.13B | — |
Dividend Yield | — | 2.62% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
